MYC and acute myeloid leukemia: An immunohistochemical analysis of MYC protein expression using bone marrow specimens of patients with untreated AML (n = 265) revealed that MYC immunopositivity of ≤6% indicated superior CR duration compared with that of >6% (23 vs. 12 months) [11].